false12-31ARYA Sciences Acquisition Corp
IV000183882151 ASTOR PLACE, 10TH FLOORNEW
YORKNASDAQ00018388212023-02-282023-02-28
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported): March 1, 2023
(February 28, 2023)
ARYA
SCIENCES ACQUISITION CORP IV
(Exact name of registrant as specified in its charter)
Cayman Islands
|
001-40122
|
98-1574672
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
51 Astor
Place, 10th Floor
New
York, NY
|
|
10003
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(212) 284-2300
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
Class A Ordinary Shares, par value $0.0001 per share
|
|
ARYD
|
|
The Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.03. Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement or a
Registrant.
As disclosed in the definitive proxy statement filed by ARYA
Sciences Acquisition Corp IV, a Cayman Islands exempted Company
(“ARYA”)
with the U.S. Securities and Exchange Commission (the “SEC”)
on February 10, 2023 (the “Extension
Proxy Statement”), relating to the extraordinary
general meeting of shareholders of ARYA (the “Extension
Meeting”), ARYA Sciences Holdings IV, a Cayman Islands
exempted company (the “Sponsor”),
agreed that if the Extension Amendment Proposal (as defined below)
was approved, it or one or more of its affiliates, members or
third-party designees (the “Lender”)
will contribute to ARYA as a loan $420,000 to be deposited into the
trust account established in connection with ARYA’s initial public
offering (the “Trust
Account”). In addition, in the event ARYA does not
consummate an initial business combination (a “Business
Combination”) by the Articles Extension Date (as defined
below), the Lender will contribute to the Company as a loan up to
$1,260,000 in nine equal installments to be deposited into the
Trust Account for each of the nine one-month optional extensions
following the Articles Extension Date.
On February 28, 2023, the shareholders of ARYA approved the
Extension Amendment Proposal at the Extension Meeting (as
described in Item 5.07 of this Current Report on Form 8-K).
Accordingly, on February 28, 2023, ARYA issued an unsecured
convertible promissory note in the principal amount of up to
$1,680,000 (the “Note”)
to the Sponsor. The Note does not bear interest and matures upon
closing of ARYA’s initial Business Combination. Up to
$1,380,000 of the amounts loaned under the Note will be convertible
at the option of the Sponsor into Class A ordinary shares, par
value $0.0001 per share, of ARYA (“Working Capital Shares”), at a
conversion price equal to $10.00 per Working Capital Share. The
terms of the Working Capital Shares will be identical to those of
the private placement shares that were issued to the Sponsor in
connection with ARYA’s initial public offering. In the event that
ARYA does not consummate a Business Combination and if the Note is
not converted into Working Capital Shares, the Note will be repaid
only from funds held outside of the Trust Account or will be
forfeited, eliminated or otherwise forgiven. The maturity date of
the Note may be accelerated upon the occurrence of an Event of
Default (as defined under the Note). Any Working Capital Shares
issuable upon conversion of the Note will not be registered under
the Securities
Act of 1933, as amended (the “Securities Act”) and will be
issued in reliance on the exemption from registration requirements
thereof provided by Section 4(a)(2) of the Securities Act. As of
February 28, 2023, $420,000 were drawn under the Note and will be
deposited in the Trust Account in connection with the Articles
Amendment (as defined below).
The foregoing description of the Note does not purport to be
complete and is qualified in its entirety by the terms and
conditions of thereof. A copy of the Note is attached hereto as
Exhibit 10.1 and incorporated herein by reference.
Item 5.03 Amendments to Articles of Association.
On February 28, 2023, ARYA held the Extension Meeting to approve an
amendment to ARYA’s amended and restated memorandum and articles of
association (the “Articles
Amendment”) to extend the date (the “Termination
Date”) by which ARYA has to consummate a Business
Combination (the “Articles
Extension”) from March 2, 2023 (the “Original
Termination Date”) to June 2, 2023 (the “Articles
Extension Date”) and to allow ARYA, without another
shareholder vote, to elect to extend the Termination Date to
consummate a Business Combination on a monthly basis up to nine
times by an additional one month each time after the Articles
Extension Date, by resolution of ARYA’s board of directors, if
requested by the Sponsor, and upon five days’ advance notice prior
to the applicable Termination Date, until March 2, 2024, or a total
of up to thirty-six months after the Original Termination Date,
unless the closing of a Business Combination shall have occurred
prior thereto (the “Extension
Amendment Proposal”). The shareholders of ARYA approved the
Extension Amendment Proposal at the Extension Meeting and on
February 28, 2023, ARYA filed the Articles Amendment with the
Registrar of Companies of the Cayman Islands.
The foregoing description is qualified in its entirety by reference
to the Articles Amendment, a copy of which is attached as Exhibit
3.1 hereto and is incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security
Holders.
On February 28, 2023, ARYA held the Extension Meeting to approve
the Extension Amendment Proposal and the Adjournment Proposal, each
as more fully described in the Extension Proxy Statement. As there
were sufficient votes to approve the Extension Amendment Proposal,
the Adjournment Proposal was not presented to shareholders.
Holders of 16,463,342 ordinary shares of ARYA held of record as of
February 3, 2023, the record date for the Extension Meeting,
entitled to vote at the Extension Meeting, were present in person
or by proxy, representing approximately 85.81% of the voting power
of ARYA’s ordinary shares as of the record date for the Extension
Meeting, and constituting a quorum for the transaction of
business.
The voting results for the Extension Amendment Proposal were as
follows:
The Extension Amendment
Proposal
ARYA had solicited proxies in favor of an Adjournment Proposal
which would have given ARYA authority to adjourn the Extension
Meeting to solicit additional proxies. As sufficient shares were
voted in favor of the Extension Amendment Proposal, this proposal
was not voted upon at the Extension Meeting.
In connection with the vote to approve
the Articles Amendment, the holders of 11,259,169 ordinary shares
of ARYA properly exercised their right to redeem their
shares (and did not withdraw their redemption) for cash at a
redemption price of approximately $10.22 per share, for an
aggregate redemption amount of approximately $115,071,882.05.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
|
|
Description
|
|
|
Amendment to Amended and Restated Memorandum and Articles of
Association.
|
|
|
Convertible Promissory Note, dated February 28, 2023 and issued to
ARYA Sciences Holdings IV.
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL
document)
|
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ARYA Sciences Acquisition Corp IV
|
|
|
|
By:
|
/s/ Michael Altman
|
|
Name:
|
Michael Altman
|
|
Title:
|
Chief Financial Officer
|